Zai shores up

How Zai Lab plans to use new cash after opting not to list in Hong Kong

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter, opting instead to raise $150 million in a NASDAQ follow-on priced Sept. 5.

Despite recent changes by Hong Kong Exchanges and Clearing Ltd. (HKEX) that allow prerevenue biotechs to list, Zai

Read the full 651 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers